Charles River Laboratories
637 hedge funds and large institutions have $9.78B invested in Charles River Laboratories in 2024 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 179 increasing their positions, 280 reducing their positions, and 83 closing their positions.
22% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 83
2.74% more ownership
Funds ownership: 100.89% → 103.62% (+2.7%)
1% more funds holding
Funds holding: 628 → 637 (+9)
5% less capital invested
Capital invested by funds: $10.3B → $9.78B (-$483M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
36% less repeat investments, than reductions
Existing positions increased: 179 | Existing positions reduced: 280
42% less call options, than puts
Call options by funds: $28.5M | Put options by funds: $49.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCP
D1 Capital Partners
New York
|
+$180M |
| 2 |
IC
Impactive Capital
New York City,
New York
|
+$159M |
| 3 |
Millennium Management
New York
|
+$68.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$64.7M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$59.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$82.7M |
| 2 |
EC
Eminence Capital
New York
|
-$72.4M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$63M |
| 4 |
ClearBridge Investments
New York
|
-$60.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$55.4M |
CRL Hedge Fund Activity: Q4 2024 in Review
637 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2024, worth a combined $9.78B — down 4.7% from $10.3B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new CRL positions and 83 closed out — a net gain of 18 holders — while 179 added to existing stakes and 280 trimmed.
The largest buyer was D1 Capital Partners, opening a new position worth an estimated $180M. The largest seller was Congress Asset Management, cutting an estimated $82.7M.
- 637 institutional investors held Charles River Laboratories (CRL) as of Q4 2024, up from 628 in Q3 2024.
- Funds reported $9.78B of Charles River Laboratories stock for Q4 2024, down 4.7% quarter-over-quarter.
- 101 funds opened new Charles River Laboratories positions in Q4 2024 and 83 closed out, a net change of +18 holders.
- The largest Charles River Laboratories buyer in Q4 2024 was D1 Capital Partners, an estimated $180M added.
- The largest Charles River Laboratories seller in Q4 2024 was Congress Asset Management, an estimated $82.7M sold.
Based on aggregated 13F filings for Q4 2024.